Cargando…

Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association

INTRODUCTION: Bacterial and fungal secondary infections following COVID-19 disease are widely being reported and are an area that should receive careful attention. Mucormycosis is a fatal fungal condition affecting immunocompromised patients caused by a group of mold mucoromycetes. Candida albicans...

Descripción completa

Detalles Bibliográficos
Autores principales: Nambiar, Manjusha, Varma, Sudhir Rama, Jaber, Mohamed, Sreelatha, S. V., Thomas, Biju, Nair, Arathi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436966/
https://www.ncbi.nlm.nih.gov/pubmed/34527182
http://dx.doi.org/10.1080/20002297.2021.1967699
_version_ 1783752085188116480
author Nambiar, Manjusha
Varma, Sudhir Rama
Jaber, Mohamed
Sreelatha, S. V.
Thomas, Biju
Nair, Arathi S.
author_facet Nambiar, Manjusha
Varma, Sudhir Rama
Jaber, Mohamed
Sreelatha, S. V.
Thomas, Biju
Nair, Arathi S.
author_sort Nambiar, Manjusha
collection PubMed
description INTRODUCTION: Bacterial and fungal secondary infections following COVID-19 disease are widely being reported and are an area that should receive careful attention. Mucormycosis is a fatal fungal condition affecting immunocompromised patients caused by a group of mold mucoromycetes. Candida albicans (C. albicans) is an oral commensal present in almost 40–65% of healthy oral cavities in adults. Several cases of mucormycosis and oral candidiasis have been reported lately in COVID-19 patients, and it may elevate the associated risks of morbidity and mortality. MATERIALS AND METHODS: Articles were taken from a period of 2020 to April 2021 using search sources such as Cochrane, PubMed, Fungiscope and Mycobank using keywords mucormycosis, Black fungus, oral candidiasis, white fungus, COVID-19, Sars-Cov-2. DISCUSSION: The development of oral mucocutaneous lesions, such as mucormycosis and candidiasis in COVID-19 patients could be due to inhaling spores resulting in pulmonary and/or sinus congestion and prolonged mechanical ventilation in the ICU settings and the long-term use of broad-spectrum antibiotics respectively. The onset of candidiasis after the emergence of COVID-19 clinical signs and symptoms varied considerably and is reported within 1–30 days in most of the cases reported in the literature. Biofilms present on the denture surfaces are predisposing factors to oral candidiasis. We aim to summarize the limited data available regarding diagnosis, clinical presentation, and therapeutic approaches for the management of Mucormycosis and oral candidiasis in COVID-19 patients. CONCLUSION: Careful monitoring of oral lesions should be instituted through interdisciplinary telemedicine and teleconsultation to aid in primary diagnosis, thereby avoiding personal attendance during the pandemic. Dental practitioners should be included among the interdisciplinary teams for exhaustive intraoral examination and reduce the risk of morbidity and mortality.
format Online
Article
Text
id pubmed-8436966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84369662021-09-14 Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association Nambiar, Manjusha Varma, Sudhir Rama Jaber, Mohamed Sreelatha, S. V. Thomas, Biju Nair, Arathi S. J Oral Microbiol Short Communication INTRODUCTION: Bacterial and fungal secondary infections following COVID-19 disease are widely being reported and are an area that should receive careful attention. Mucormycosis is a fatal fungal condition affecting immunocompromised patients caused by a group of mold mucoromycetes. Candida albicans (C. albicans) is an oral commensal present in almost 40–65% of healthy oral cavities in adults. Several cases of mucormycosis and oral candidiasis have been reported lately in COVID-19 patients, and it may elevate the associated risks of morbidity and mortality. MATERIALS AND METHODS: Articles were taken from a period of 2020 to April 2021 using search sources such as Cochrane, PubMed, Fungiscope and Mycobank using keywords mucormycosis, Black fungus, oral candidiasis, white fungus, COVID-19, Sars-Cov-2. DISCUSSION: The development of oral mucocutaneous lesions, such as mucormycosis and candidiasis in COVID-19 patients could be due to inhaling spores resulting in pulmonary and/or sinus congestion and prolonged mechanical ventilation in the ICU settings and the long-term use of broad-spectrum antibiotics respectively. The onset of candidiasis after the emergence of COVID-19 clinical signs and symptoms varied considerably and is reported within 1–30 days in most of the cases reported in the literature. Biofilms present on the denture surfaces are predisposing factors to oral candidiasis. We aim to summarize the limited data available regarding diagnosis, clinical presentation, and therapeutic approaches for the management of Mucormycosis and oral candidiasis in COVID-19 patients. CONCLUSION: Careful monitoring of oral lesions should be instituted through interdisciplinary telemedicine and teleconsultation to aid in primary diagnosis, thereby avoiding personal attendance during the pandemic. Dental practitioners should be included among the interdisciplinary teams for exhaustive intraoral examination and reduce the risk of morbidity and mortality. Taylor & Francis 2021-08-26 /pmc/articles/PMC8436966/ /pubmed/34527182 http://dx.doi.org/10.1080/20002297.2021.1967699 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Nambiar, Manjusha
Varma, Sudhir Rama
Jaber, Mohamed
Sreelatha, S. V.
Thomas, Biju
Nair, Arathi S.
Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title_full Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title_fullStr Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title_full_unstemmed Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title_short Mycotic infections – mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association
title_sort mycotic infections – mucormycosis and oral candidiasis associated with covid-19: a significant and challenging association
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436966/
https://www.ncbi.nlm.nih.gov/pubmed/34527182
http://dx.doi.org/10.1080/20002297.2021.1967699
work_keys_str_mv AT nambiarmanjusha mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation
AT varmasudhirrama mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation
AT jabermohamed mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation
AT sreelathasv mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation
AT thomasbiju mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation
AT nairarathis mycoticinfectionsmucormycosisandoralcandidiasisassociatedwithcovid19asignificantandchallengingassociation